Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MOUNTAINEER LABORATORIES LLC

NPI: 1629520853 · POINT PLEASANT, WV 25550 · Clinical Medical Laboratory · NPI assigned 11/04/2016

$3.71M
Total Medicaid Paid
43,695
Total Claims
19,738
Beneficiaries
9
Codes Billed
2018-01
First Month
2024-02
Last Month

Provider Details

Authorized OfficialBOWEN, JAMES (OWNER)
NPI Enumeration Date11/04/2016

Related Entities

Other providers sharing the same authorized official: BOWEN, JAMES

ProviderCityStateTotal Paid
NEW LIFECLINICS INC POINT PLEASANT WV $6.50M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,623 $293K
2019 7,215 $502K
2020 9,511 $918K
2021 10,222 $961K
2022 9,896 $935K
2023 2,106 $93K
2024 122 $3K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 21,219 9,389 $2.60M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 19,853 8,601 $958K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,441 898 $75K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 410 340 $47K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 592 353 $29K
84443 Thyroid stimulating hormone (TSH) 48 42 $258.76
80061 Lipid panel 33 28 $151.92
85025 Blood count; complete (CBC), automated, and automated differential WBC count 34 29 $88.77
36415 Collection of venous blood by venipuncture 65 58 $70.57